BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
- None.
- None.
The public offering by BIOLASE, Inc. indicates a capital-raising event that will likely dilute current shareholders but provide the company with necessary funds to potentially expand operations, invest in R&D, or pay off existing debts. The pricing of the units at $0.44 suggests a valuation adjustment that investors will scrutinize. The inclusion of both Class A and Class B Warrants with different exercise prices and conditions adds complexity to the offering. These warrants could incentivize investors through the potential for future equity at a set price, yet they also introduce a potential for further dilution.
Considering the gross proceeds of approximately $7.0 million before fees and expenses, the impact on the company's financial position should be evaluated against its current burn rate and capital requirements. The immediate exercisability of Class A Warrants could lead to a short-term influx of capital if investors choose to exercise these rights, albeit it may also result in a more pronounced dilution effect.
From a market perspective, the performance of BIOLASE's stock post-announcement will be indicative of investor sentiment regarding the company's growth prospects and the attractiveness of the offering. The relatively low unit price could be perceived as an entry point for new investors or a red flag signaling a lack of confidence. Historical performance of similar offerings in the dental laser industry might offer a benchmark for expectations.
Furthermore, the role of Lake Street Capital Markets, LLC and Maxim Group LLC as joint placement agents is pivotal. Their reputation and ability to generate interest in the offering can significantly influence its success. It will be essential to monitor the aftermarket performance of the units and the exercise of the warrants, as these will provide insights into the long-term market confidence in BIOLASE's strategic direction and financial health.
The offering's compliance with SEC regulations, as indicated by the effectiveness of the Registration Statement, is crucial for the legitimacy of the transaction. The requirement that the securities can only be sold in certain jurisdictions and under specific conditions highlights the legal intricacies of public offerings. The role of the prospectus is to provide transparency and protect investors, which is why its availability and the accuracy of its contents are significant.
Investors must consider the legal implications of the Class B Warrants, which are contingent on stockholder approval, indicating a level of uncertainty in the terms of the offering. The legal framework surrounding these warrants will dictate the timeline and conditions under which they can be exercised, which in turn could affect the company's stock performance and investor relations.
LAKE FOREST, CA / ACCESSWIRE / February 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit is being sold at an effective public offering price of
Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately
Lake Street Capital Markets, LLC and Maxim Group LLC are acting as joint placement agents for the offering.
The securities described above are being offered pursuant to a registration statement on Form S-1, as amended (File No. 333- 276596) (the "Registration Statement"), which was declared effective by the Securities and Exchange Commission (the "SEC") on February 13, 2024. The offering is being made only by means of a prospectus which is a part of the Registration Statement. A preliminary prospectus relating to the offering has been filed with the SEC. Copies of the final prospectus relating to this offering, when available, will be filed with the SEC and may be obtained from Lake Street Capital Markets, LLC, Attn: Syndicate Department, 920 Second Avenue South, Suite 700, Minneapolis, MN 55402, by calling (612) 326-1305 or Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, NY 10022, at (212) 895-3745.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. As of December 31, 2023, BIOLASE's proprietary laser products incorporate approximately 241 patented and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. From 1998 through December 31, 2023, BIOLASE has sold over 47,700 laser systems in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.
BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. The forward-looking statements include statements regarding the expected closing date of the offering. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, those risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's Annual Report filed on Form 10-K filed with the SEC and other filings by BIOLASE with the SEC. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.
Investor Relations:
EVC Group LLC
Michael Polyviou / Todd Kehrli
(732) 933-2754
mpolyviou@evcgroup.com / tkehrli@evcgroup.com
SOURCE: BIOLASE, Inc.
View the original press release on accesswire.com
FAQ
What is the offering price of each unit in BIOL's public offering?
How many units are included in BIOL's public offering?
Who are the joint placement agents for BIOL's offering?
What are the expected gross proceeds from BIOL's public offering?
When is the expected closing date for BIOL's public offering?
